Vanda Pharmaceuticals Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Fanapt at $117.3 million, 54% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
229
|
216
|
199
|
193
|
254
|
269
|
248
|
227
|
193
|
165
|
146
|
| Fanapt |
138
+24.2%
share 60.0%
|
117
+24.4%
share 54.3%
|
94
+3.8%
share 47.4%
|
91
-4.1%
share 47.2%
|
95
-0.4%
share 37.2%
|
95
+8.8%
share 35.4%
|
87
+3.9%
share 35.3%
|
84
+9.0%
share 37.1%
|
77
+2.9%
share 40.0%
|
75
share 45.5%
|
—
|
| Hetlioz |
60
-20.6%
share 26.0%
|
71
-6.8%
share 33.1%
|
77
-23.5%
share 38.6%
|
100
-37.3%
share 52.0%
|
160
-8.0%
share 62.8%
|
174
+8.0%
share 64.6%
|
161
+12.4%
share 64.7%
|
143
+23.4%
share 62.9%
|
116
+28.7%
share 60.0%
|
90
share 54.5%
|
—
|
| PONVORY |
30
+12.4%
share 12.9%
|
27
-1.5%
share 12.7%
|
28
+1637.5%
share 14.0%
|
2
share 0.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VNDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Washington, DC
- SEC filer status
- Accelerated filer
- SEC CIK
- 1347178
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.